Bioassay for detection of methotrexate in serum

References

• Seitz M. Molecular and cellular effects of methotrexate. CUff Opin Rheumatol 1999;11:226–32.
   PubMedGoogle Scholar
• Fairbanks LD, Ruckemann K, Qiu Y, Hawrylowicz CM, Richards DF, Swaminathan R, et al. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999;342(Pt 1): 143–52.
   PubMedGoogle Scholar
• Smolenska Z, Kaznowska Z, Zarowny D, Simmonds HA, Smolenski RT. Effect of methotrexate on blood purine and pyrimidine levels in patients with rheumatiod arthritis. Rheumatology 1999;38:997–1002.
   Google Scholar
• Bertino JR. Kamofsky memorial lecture. Ode to metho-trexate. J Clin Oncol 1993;11:5–14.
   PubMed Web of Science ®Google Scholar
• Shiroky JB, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993;36:795–803.
   PubMed Web of Science ®Google Scholar
• Kremer JM. Methotrexate update. Scand J Rheumatol 1996;25:341–4.
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Merriman RC, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis Rheum 1994;37:1492–8.
   PubMed Web of Science ®Google Scholar
• Lacaille D, Stein HB, Raboud J, Klinkhoff AV. Longterm therapy of psoriatic arthritis: intramuscular gold or metho-trexate? J Rheumatol 2000;27:1922–7.
   PubMed Web of Science ®Google Scholar
• Chan ESL, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266–73.
   PubMedGoogle Scholar
• Genestier L, Paillot R, Foumel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998;102:322–8.
   PubMed Web of Science ®Google Scholar
• de Lathouder S, Gerards AH, de Groot ER, Valkhof M, Aarden LA. Mycophenolic acid and methotrexate inhibit lymphocyte cytokine production via different mechanisms. Eur Cytokine Netw 2002;13:317–23.
   Google Scholar
• Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino JS, Jr. Methotrexate pharmacokinetics in patients with rheuma-toid arthritis. J Rheumatol 1989;16:745–8.
   PubMedGoogle Scholar
• Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol 1995;22:844–9.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Di Fuccia G, Molinaro M, Ramenghi B, Zonta L, Regazzi MB, et al. Plasma levels after oral methotrexate in children with juvenile rheumatoid arthritis. J Rheumatol 1993;20:1573–7.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Galivan J, Streckfuss A, Kamen B. Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. Arthritis Rheum 1986;29:832–5.
   Google Scholar
• Slordal L, Prytz PS, Pettersen I, Aarbakke J. Methotrexate measurements in plasma: comparison of enzyme multiplied immunoassay technique, TDx fluorescence polarization immuno-assay, and high pressure liquid chromatography. Ther Drug Monit 1986;8:368–72.
   PubMedGoogle Scholar
• Schroder H, Heinsvig E. Enzymatic asay for methotrexate in erytrocytes. Scand J Clin Lab Invest 1985;45:657–9.
   PubMed Web of Science ®Google Scholar
• Weigand M, Frei E, Graf N, Buchholz B, Wolfrom C, Breuer A, Wiessler M. Mechanisms of resistance to methotrexate in childhood acute lymphoblastic leukemia: circumvention of thymidylate synthase inhibition. J Cancer Res Clin Oncol 1999;125:513–9.
   Google Scholar
• Angelis-Stoforidis P, Vajda FJ, Christophidis N. Methotrex-ate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin Exp Rheumatol 1999;17:313–20.
   Google Scholar
• Kamen BA, Takach PL, Vatev R, Caston JD. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54–63.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Nielsen S, Karup PF, Zak M. Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis. Scand J Rheuma-tol 2000;29:187–9.
   PubMed Web of Science ®Google Scholar
• Aarden LA, de Groot ER, Schaap OL, Lansdorp PM. Production of hybridoma growth factor by human monocytes. Eur J Immunol 1987;17:1411–6.
   PubMed Web of Science ®Google Scholar
• K Diem, C Lentner. Documenta Geigy. Wissenschaftliche Tabellen. Basle, Switzerland: JR Geigy AG, Pharma; 1968.
   Google Scholar
• Sano H, Kubota M, Kasai Y, Hashimoto H, Shimizu T, Adachi S, et al. Increased methotrexate-induced DNA strand breaks and cytotoxicity following mutational loss of thymi-dine kinase. Int J Cancer 1991;48:92–5.
   PubMedGoogle Scholar
• Wallace CA, Bleyer WA, Sherry DD, Salmonson KL, Wedgwood RJ. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989;32:677–81.
   PubMedGoogle Scholar
• Edelman J, Biggs DF, Jamali F, Russell AS. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984;35:382–6.
   PubMedGoogle Scholar
• Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 2002;29:2077–83.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol 1995;22: 38–40.
   Google Scholar
• Bressolle F, Bologna C, Kinowski JM, Arcos B, Sany J, Combe B. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997;24:1903–9.
   PubMed Web of Science ®Google Scholar
• Bressolle F, Kinowski JM, Morel J, Pouly B, Sany J, Combe B. Folic acid alters methotrexate availability in patients with rheumatoid arthritis. J Rheumatol 2000;27:2110–4.
   PubMed Web of Science ®Google Scholar
• Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994;53:475–7.
   PubMed Web of Science ®Google Scholar
• Gerards AH, de Lathouder S, de Groot ER, Dijkmans BA, Aarden LA. Inhibition of cytokine production by methotrexate — studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 2003;42:1189 — 96.
   PubMedGoogle Scholar
• Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, et al. The effect of folic acid supple-mentation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990;33: 9–18.
   PubMed Web of Science ®Google Scholar
• van Ede AE, Laan RF, Blom HJ, Boers GH, Haagsma Thomas CM, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:658–65.
   PubMed Web of Science ®Google Scholar